Needle-Free Injection Systems Market Size, Share & Trends Analysis Report  By Product (Fillable Needle-Free Injectors, Prefilled Needle-Free Injectors), By Technology (Jet-Based Needle-Free Injectors, Spring-Based Needle-Free Injectors, Laser-Powered Needle-Free Injectors, Vibration-Based Needle-Free Injectors), By Usability (Reusable Needle-Free Injectors, Disposable Needle-Free Injectors), By Type of Medication (Liquid-based needle-free injectors, Powder-based needle-free injectors, Projectile/depot-based needle-free injectors), By Site of Delivery (Intra dermal injectors, Intramuscular injectors, Subcutaneous injectors), By Application (Vaccine Needle-free delivery, Insulin Needle-free delivery, Pain Management Needle-free delivery, Oncology Needle-free delivery, Others applications), By End User (Hospitals and Clinics, Homecare Settings, Research Laboratories, Pharmaceutical and Biotechnology companies, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global needle-free injection systems market size was valued at USD 18.9 billion in 2022. It is projected to reach USD 71.8 billion by 2031, growing with a CAGR of 16% during the forecast period (2023–2031).

Needle-free injection system contains a wide variety of drug delivery methods that drive drugs through the skin, utilizing forces such as Lorentz, Shock waves, pressure by gas, or electrophoresis, effectively eliminating the need for a hypodermic needle. The use of needle-free injection systems is an innovative technique to provide different medications to patients without piercing their skin with a traditional needle. An additional benefit of the technology is the ability of technically advanced needle-free injection systems to administer highly viscous medication formulations that cannot be administered by conventional needle and syringe systems. Future medicine administration will be almost painless and incredibly effective due to this technology. A number of institutions, including the World Health Organization and the Centers for Disease Control and Prevention, and others, are supporting this technology.

The increasing prevalence of diabetes is influencing the demand for needle-free injection systems on account of administrating accurate doses of insulin. Furthermore, frequent monitoring of blood sugar with needles increases the risk of infection and pain among individuals. Moreover, surging demand and technological advancements in the field of pain-free and self-administration drugs are propelling the growth of the market. For instance, in 2015, Zogenix launched DosePro, a needle-free medication transportation technology, which is a prefilled, single-use, and disposable subcutaneous medicine transportation system for the self-administration of liquid medicine formulations. The increasing prevalence of infectious diseases such as hepatitis, dengue fever, neurological disorders, and AIDS virus via syringe is also encouraging the need for needle-free injections. For instance, as per the U.S. organization for HIV, about 37 million people were diagnosed with HIV infection worldwide.

Market Dynamics

Global Needle-Free Injection Systems Market Drivers

Communicable Diseases Brought on by Needle Stick Injuries

Although needlestick injuries have decreased as a result of widespread measures and safety-conscious needle designs, they still do happen. Healthcare practitioners can use a model created by the Centers for Disease Control and Prevention to determine when to begin antiretroviral medication. The most affected employees were the nurses because syringe disposal was so widespread. In contrast, there was a higher frequency of NSIs among doctors, where surgical gadgets were the main cause. As a result, the market is expected to rise at a faster rate over the projected period due to the rising frequency of communicable diseases caused by needle stick injuries.

Regional Analysis

Geographically, the needle-free injection systems market is segmented into North America, Europe, Asia Pacific, Latin America, and The Middle East & Africa (LAMEA).

North America is likely to hold the largest share of the global needle-free injection system market during the forecast period. The rising demand for vaccination in pediatric patients is increasing demand of the market. The region's market is expanding as a result of factors including rising demand for biologics, technical improvements, mergers and acquisitions by significant market players, advantageous reimbursement policies, rising healthcare costs, and regulatory approvals of innovative injectable systems. In hospital settings, it is well known that there are many instances of significant needlestick injuries. The potential of needlestick injuries is always a concern because millions of healthcare workers in North America use needles on a regular basis. Surgeons, emergency department staff, lab professionals, and nurses are among the healthcare workers most at risk for needle stick wounds. Despite the fact that every hospital has policies in place regarding the safe handling and disposal of needles, as well as the most recent designs of safety-conscious needles, needle stick injuries still happen. Most often, reckless behavior and extreme negligence are to blame for needle stick injuries. Thus, the rise in needlestick injuries in the area is propelling the market's expansion during the projection year.

Europe is expected to be the second leading region in the global needle-free injection system market. The increasing number of incidences of diabetes is propelling the growth of needle-free insulin devices. For instance, according to World Health Organization, around 4.1 million people suffer from diabetes in the U.K. The market expansion in Europe is also being driven by mergers and acquisitions of significant industry players, advantageous reimbursement policies, rising healthcare costs, and regulatory approvals of innovative injection systems.

Asia Pacific (APAC) is expected to be the fastest-growing region during the forecast period. This is attributed to an increasing prevalence of chronic diseases and communicable diseases due to needlestick injuries in the region. The increasing prevalence of diabetes in India and China is boosting the growth of the market. The technology is extremely useful for the pharmaceutical industry and is becoming popular in developing nations in the region because it is used in mass vaccination campaigns, nullifying the risk of needle stick injuries and preventing other complications, such as those brought on by the repeated use of a single needle.

LAMEA is expected to witness sluggish growth in the global market during the forecast period. This is attributed to the poor healthcare infrastructure in Africa and slow-growing economies. However, improving healthcare infrastructure and high disposable income in Middle East countries are driving growth in the region. The demand for these systems is growing as a result of the elimination of needle hazards and cost-savings in healthcare. Due to recent advancements in these systems, demand has grown significantly. However, the market's expansion in the region would be constrained by reasons such as a lack of qualified experts and the restricted adoption of needle-free injection methods for the administration of drugs.

Segmental Analysis

The global needle-free injection systems market is segmented by product, technology, type of medication, usability, side of delivery, application, and end users.

Based on product type, the market is segmented into fillable needle-free injectors and prefilled needle-free injectors.

Prefilled syringe sales have increased mostly due to factors such as ease of use, convenience for end users and healthcare professionals, and ease of usage at home. They are easier to use in emergency circumstances. Minimization of medication mistakes, improved dosage precision, greater certainty of sterility, and simpler storage and disposal lead to increased usage.

On the basis of technology, the needle-free injection systems market is segmented into spring-based needle-free injectors, vibration-based needle-free injectors, laser-powered needle-free injectors, and jet-based needle-free injectors.

Based on usability, the needle-free injection systems market is segmented into disposable needle-free injectors and reusable needle-free injectors.

On the basis of the type of medication, the needle-free injection systems market is segmented into Projectile/depot-based needle-free injectors, powder-based needle-free injectors, and Liquid-based needle-free injectors.

Liquid-based needle-free injectors dominate the market. It is the first needle-free injection system variation and is still being developed by top players in the pharmaceutical sector. The ability of a liquid jet strong enough to pierce the skin and the underlying fat layer without damaging the skin and the integrity of the drug molecule is crucial to the overall process of a successful injection using a needle-free device.

Based on the site of delivery, the market is segmented into intradermal injectors, intramuscular injectors, and subcutaneous injectors.

The subcutaneous injectors segment is expected to dominate the market owing to the rising preference of patients towards self-administration of drugs. The adipose layer beneath the skin receives the medication. This technique has been used to deliver various therapeutic proteins, such as human growth hormones.

Based on the application, the market is segmented into vaccine needle-free delivery, pain management needle-free delivery, oncology needle-free delivery, insulin needle-free delivery, and other applications.

Based on end-user, the market is segmented into clinics and hospitals, home care settings, research laboratories, pharmaceutical, biotechnology companies, and other end users.

Recent Developments

• October 2022- A distributorship agreement was reached by Science - Link Trading, a business whose goal is to assist in the commercialization of emerging disruptive technologies, and NuGen Medical Devices Inc., a pioneer in needle-free medicine delivery. The Agreement commits to 34,000 InsuJet devices over five years and includes extra accessories.
• June 2022- The latest prototype of NovaXS Biotech's smart medical device for needle-free injectable therapy was unveiled. Telosis, a patent-pending device from NovaXS, was created to deliver a narrow stream of medication without a needle in 0.3 seconds and evaluate injection data to allow smarter medical choices.